Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
P020
- Development stage
- Preclinical
- Lead developer
- Abbisko Therapeutics
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
P020 is an investigational bispecific antibody-drug conjugate (ADC) being developed by Abbisko Therapeutics for the treatment of solid tumors. The program is currently in the preclinical lead optimization stage. P020 is designed to target tumor-associated antigens on solid tumors, leveraging a bispecific antibody architecture conjugated to a cytotoxic payload to selectively deliver therapeutic agents to cancer cells while minimizing systemic toxicity.
Beyond the preview
Go deeper on P020.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on P020.